pd 98059 and atorvastatin

pd 98059 has been researched along with atorvastatin in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H1
Goez, P; Hagelgans, A; Hempel, U; Heyne, B; Jaross, W; Menschikowski, M; Neumeister, V; Siegert, G1
Hirade, K; Ishisaki, A; Kozawa, O; Matsuno, H; Nakajima, K; Suga, H1
Hirase, T; Inoue, T; Node, K; Wang, D1
Chen, G; Deng, CQ; Wu, L1

Other Studies

5 other study(ies) available for pd 98059 and atorvastatin

ArticleYear
Identifying off-target effects and hidden phenotypes of drugs in human cells.
    Nature chemical biology, 2006, Volume: 2, Issue:6

    Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship

2006
Statins potentiate the IFN-gamma-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells.
    Biochimica et biophysica acta, 2005, Apr-15, Volume: 1733, Issue:2-3

    Topics: Amides; Aorta; Atorvastatin; Bacterial Proteins; Bacterial Toxins; Butadienes; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Drug Synergism; Flavonoids; Group II Phospholipases A2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Janus Kinase 2; Lovastatin; Myocytes, Smooth Muscle; NF-kappa B; Nitriles; Phospholipases A; Phospholipases A2; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyridines; Pyrroles; RNA Stability; Up-Regulation

2005
Differential roles of MAP kinases in atorvastatin-induced VEGF release in cardiac myocytes.
    Life sciences, 2006, Aug-15, Volume: 79, Issue:12

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blotting, Western; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flavonoids; Heptanoic Acids; Imidazoles; Mice; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Myocytes, Cardiac; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Pyrroles; Vascular Endothelial Growth Factor A

2006
Atorvastatin inhibits angiotensin II-induced T-type Ca2+ channel expression in endothelial cells.
    Biochemical and biophysical research communications, 2006, Aug-25, Volume: 347, Issue:2

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Calcium Channels, T-Type; Cells, Cultured; Endothelial Cells; Flavonoids; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Microscopy, Fluorescence; Pyrroles; ras Proteins; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tetrazoles; Vasoconstrictor Agents

2006
The effects of BuYang HuanWu Decoction and its effective components on proliferation-related factors and ERK1/2 signal transduction pathway in cultured vascular smooth muscle cells.
    Journal of ethnopharmacology, 2011, Apr-26, Volume: 135, Issue:1

    Topics: Alkaloids; Animals; Atorvastatin; Cardiovascular Agents; Cell Cycle; Cell Proliferation; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Drugs, Chinese Herbal; Dual Specificity Phosphatase 1; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Glycosides; Heptanoic Acids; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Platelet-Derived Growth Factor; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction

2011